Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers.
暂无分享,去创建一个
Michael Jones | Julian Peto | Thomas Brüning | Kamila Czene | Alfons Meindl | Thilo Dörk | Barbara Burwinkel | Arto Mannermaa | Annegien Broeks | Henrik Flyger | John L Hopper | Hermann Brenner | Kenneth Offit | Caroline Seynaeve | Per Hall | Manjeet K Bolla | Heli Nevanlinna | Irene L Andrulis | Angela Cox | Peter A Fasching | Annika Lindblom | Georgia Chenevix-Trench | Anthony Swerdlow | Vessela Kristensen | Julia A Knight | Simon S Cross | Volker Arndt | Argyrios Ziogas | Ian Tomlinson | Roger L Milne | Olivia Fletcher | Sten Cornelissen | Anja Rudolph | Qin Wang | Alison M Dunning | Hoda Anton-Culver | Anna Jakubowska | Jan Lubinski | Hiltrud Brauch | Maartje Hooning | Montserrat García-Closas | Graham G Giles | Jenny Chang-Claude | Paul D P Pharoah | Fergus J Couch | Jonine Figueroa | Douglas F Easton | Mark Robson | Veli-Matti Kosma | Alice S Whittemore | Peter Hillemanns | Mieke Schutte | Melissa C Southey | Antoinette Hollestelle | Quinten Waisfisz | Amy Trentham-Dietz | Rita K Schmutzler | Celine Vachon | A. Whittemore | S. Cross | P. Fasching | C. Vachon | K. Czene | P. Hall | F. Couch | H. Brenner | J. Chang-Claude | M. García-Closas | G. Giles | J. Hopper | E. John | A. Spurdle | T. Dörk | M. Southey | A. Cox | D. Easton | A. Hollestelle | A. Broeks | P. Pharoah | J. Peto | E. Khusnutdinova | K. Offit | A. Antoniou | H. Brauch | M. Schutte | V. Kristensen | P. Hillemanns | A. Ziogas | H. Anton-Culver | A. Dunning | O. Fletcher | G. Chenevix-Trench | S. Bojesen | H. Nevanlinna | N. Bogdanova | R. Tollenaar | R. Milne | A. Mannermaa | V. Kosma | A. Lindblom | M. Schmidt | M. Bolla | Qin Wang | Andrew Lee | T. Muranen | Q. Waisfisz | M. Adank | A. Meindl | R. Schmutzler | H. Flyger | A. Rudolph | B. Burwinkel | E. Sawyer | I. Tomlinson | I. Andrulis | J. Knight | S. Margolin | M. Hooning | L. Haeberle | V. Arndt | A. Swerdlow | J. Figueroa | T. Brüning | C. Seynaeve | A. Jakubowska | J. Lubiński | N. Antonenkova | A. Trentham-Dietz | P. Newcomb | M. Bermisheva | T. Park-Simon | A. V. D. van den Ouweland | M. Robson | F. Hogervorst | S. Cornelissen | L. van der Kolk | H. Surowy | Amanda B Spurdle | Sara Margolin | Rob A E M Tollenaar | Antonis C Antoniou | Marjanka K Schmidt | Polly A Newcomb | Elinor J Sawyer | Elza Khusnutdinova | Esther M John | Lothar Haeberle | Ans van den Ouweland | Marina Bermisheva | Andrew Lee | Tjoung-Won Park-Simon | Harald Surowy | Taru A Muranen | Natalia V Bogdanova | Natalia N Antonenkova | E. Galle | Lizet van der Kolk | Stig Bojesen | Muriel A Adank | Frans Hogervorst | Richard van Hien | Hanne Meijers | Eva Galle | Julie Soens | A. Lee | J. Soens | H. Meijers | R. van Hien | Michael P. Jones | P. Hall
[1] The Polish Breast Cancer Consortium. Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002 .
[2] D. Clayton,et al. Empirical Bayes estimates of age-standardized relative risks for use in disease mapping. , 1987, Biometrics.
[3] J. Martens,et al. Excess breast cancer risk in first degree relatives of CHEK2∗1100delC positive familial breast cancer cases. , 2013, European journal of cancer.
[4] P. Devilee,et al. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation , 2000, The Lancet.
[5] Jaana M. Hartikainen,et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk , 2013, Nature Genetics.
[6] 前田 邦彦,et al. 山形県の乳癌の病理学的特性-HER2 (human epidermal growth factor receptor 2)の発現率に関する調査- , 2010 .
[7] A. Ashworth,et al. Family History, Genetic Testing, and Clinical Risk Prediction: Pooled Analysis of CHEK2*1100delC in 1,828 Bilateral Breast Cancers and 7,030 Controls , 2009, Cancer Epidemiology Biomarkers & Prevention.
[8] S. Bojesen,et al. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] D. Horsman,et al. Frequency of the CHEK2 1100delC mutation among women with breast cancer: an international study. , 2008, Cancer research.
[10] M. Schutte,et al. Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant , 2004, Journal of Medical Genetics.
[11] D. Easton,et al. BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface , 2013, British Journal of Cancer.
[12] A. W. van der Vaart,et al. CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women , 2011, Journal of Medical Genetics.
[13] Nazneen Rahman,et al. Gene-panel sequencing and the prediction of breast-cancer risk. , 2015, The New England journal of medicine.
[14] T. Dörk,et al. Breast cancer in patients carrying a germ-line CHEK2 mutation: Outcome after breast conserving surgery and adjuvant radiotherapy. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[15] J. Peterse,et al. Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] P. Ang,et al. CHEK2*1100delC screening of Asian women with a family history of breast cancer is unwarranted. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Nazneen Rahman,et al. Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility. , 2003, American journal of human genetics.
[18] Jiri Bartek,et al. Chk1 and Chk2 kinases in checkpoint control and cancer. , 2003, Cancer cell.
[19] T. Hupp,et al. The regulation of CHK2 in human cancer , 2004, Oncogene.
[20] Jane E. Carpenter,et al. Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants , 2015, JNCI Journal of the National Cancer Institute.
[21] S. Cross,et al. CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] P. V. van Diest,et al. One-time general consent for research on biological samples: Opt out system for patients is optimal and endorsed in many countries , 2006, BMJ : British Medical Journal.
[23] A. Jakubowska,et al. CHEK2-Positive Breast Cancers in Young Polish Women , 2006, Clinical Cancer Research.
[24] Stephen W Duffy,et al. Risk determination and prevention of breast cancer , 2014, Breast Cancer Research.
[25] Nazneen Rahman,et al. CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. , 2004, American journal of human genetics.
[26] L. Kuller. Breast cancer study. , 1988, Science.
[27] J. Foekens,et al. Gene expression profiling assigns CHEK2 1100delC breast cancers to the luminal intrinsic subtypes , 2012, Breast Cancer Research and Treatment.
[28] Y Taya,et al. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. , 2000, Genes & development.